China’s National Medical Products Administration has officially approved an indigenously developed Alzheimer’s drug called GV-971 (sodium oligo-mannurarate). The Shanghai Institute of Materia Medica (SIMM) under the Chinese Academy of Sciences, which has developed the drug jointly with the Ocean University of China and Green Valley Pharmaceutical Co Ltd, after 22 years of research. Extracted from brown algae, the oral drug is the world’s first multi-targeting and carbohydrate-based drug, which will now be available to patients from December,29,2019.
Static/Current Takeaways Important For RRB NTPC/SSC CGL:
- Alzheimer disease is an irreversible, progressive brain disorder that slowly destroys memory, thinking ability, and the capability to carry out simple tasks.
Source: The Times of India